Gyroscope Therapeutics is a clinical-stage gene therapy company developing treatments for diseases of the eye that cause vision loss and blindness. Its lead candidate, GT005, is an AAV2-based, one-time subretinal gene therapy designed to increase production of Complement Factor I (CFI) to rebalance an overactive complement system implicated in AMD. GT005 has been granted Fast Track designation by the U.S. Food and Drug Administration and is being evaluated in Phase II clinical trials for geographic atrophy secondary to age-related macular degeneration (GA). Gyroscope plans to use proceeds from the Sanofi investment to support funding of ongoing clinical trials of GT005 in GA. The company is led by CEO Khurem Farooq and is headquartered in London, with locations in Philadelphia and San Francisco. Gyroscope Therapeutics is a clinical-stage gene therapy company focused on developing one-time AAV-based treatments for eye diseases, primarily geographic atrophy (GA) secondary to age‑related macular degeneration (AMD). Its lead investigational therapy, GT005, is an AAV2-based gene therapy designed to increase production of Complement Factor I (CFI) to modulate an overactive complement system and is delivered under the retina. GT005 has received Fast Track designation from the U.S. FDA and is being evaluated in Phase II trials (EXPLORE and HORIZON) and earlier Phase I/II (FOCUS) studies in genetically defined and broader GA populations. Gyroscope also develops a proprietary OrbitTM subretinal delivery system for precise posterior eye delivery and maintains a manufacturing platform and surgical delivery capabilities. Proceeds from the announced financing are earmarked to advance GT005’s clinical development, expand the early-stage pipeline, and further develop the delivery technology. The company is headquartered in London with locations in Philadelphia and San Francisco and is supported by a syndicate of life sciences investors.

Total raised

$208M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2021